Aeglea BioTherapeutics, Inc. Uncategorized Contracts & Agreements
48 Contracts & Agreements
- Second Amended and Restated Antibody Discovery and Option Agreement, dated May 14, 2024, by and between the Company, Paragon Therapeutics, Inc. and Parapyre Holding LLC (Filed With SEC on August 7, 2024)
- Amendment No. 1 to (Filed With SEC on May 9, 2024)
- Offer Letter, dated August 18, 2023, by and between the Company and Heidy King-Jones (Filed With SEC on March 1, 2024)
- Offer Letter, dated August 1 (Filed With SEC on February 29, 2024)
- Spyre Therapeutics, Inc (Filed With SEC on February 29, 2024)
- Description of the Registrant's securities (Filed With SEC on February 29, 2024)
- Amended and Restated Offer Letter, dated November 22, 2023 and as amended on February 1, 2024, by and between the Company and Cameron Turtle (Filed With SEC on February 5, 2024)
- Amendment to the Amended and Restated Letter Agreement by and between the Company and Cameron Turtle, dated as of February 1, 2024 (Filed With SEC on February 5, 2024)
- Offer Letter, dated August 10, 2023, by and between the Company and Scott Burrows (Filed With SEC on December 22, 2023)
- Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and the First Amendment, Second Amendment, Third Amendment and Fourth Amendment thereto (Filed With SEC on December 22, 2023)
- Amended and Restated Antibody Discovery and Option agreement, dated September 29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC (Filed With SEC on December 22, 2023)
- Amended and Restated Offer Letter, dated November 22, 2023, by and between the Company and Cameron Turtle (Filed With SEC on December 22, 2023)
- Novation Agreement, dated September 19, 2023, by and between Paragon Therapeutics, Inc., the Company and WuXi Biologics (Hong Kong) Limited (Filed With SEC on December 22, 2023)
- Form of Pre-Funded Warrants 2022 (Filed With SEC on December 22, 2023)
- Amended and restated letter agreement by and between the Company and Cameron Turtle, dated as of November 22, 2023 (Filed With SEC on November 28, 2023)
- Offer Letter, dated August 10, 2023, by and between the Company and Scott Burrows (Filed With SEC on November 15, 2023)
- Third Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)
- First Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)
- 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)
- Offer Letter, dated June 22, 2023, by and between Aeglea BioTherapeutics, Inc. and Cameron Turtle (Filed With SEC on November 15, 2023)
- Form of Pre-Funded Warrants 2022 (Filed With SEC on November 15, 2023)
- Second Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on October 10, 2023)
- Amended and Restated Antibody Discovery and Option agreement, dated September 29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC (Filed With SEC on October 10, 2023)
- Novation Agreement, dated September 19, 2023, by and between Paragon Therapeutics, Inc., Aeglea BioTherapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 10, 2023)
- Offer Letter by and between the Company and Scott Burrows, dated as of August 10, 2023 (Filed With SEC on September 5, 2023)
- First Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on August 11, 2023)
- Antibody Discovery and Option agreement, dated May 25, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, Inc (Filed With SEC on August 11, 2023)
- Offer Letter, dated June 22, 2023, by and between Aeglea BioTherapeutics, Inc. and Cameron Turtle (Filed With SEC on August 11, 2023)
- Offer Letter, dated June 14, 2021 issued by the Registrant to Mr. Jonathan Alspaugh (Filed With SEC on March 8, 2022)
- Description of the Registrant's securities (Filed With SEC on March 18, 2021)
- Offer letter, dated March 13, 2020 issued by the Registrant to Dr. Leslie Sloan (Filed With SEC on May 7, 2020)
- Description of the Registrant's securities (Filed With SEC on February 24, 2020)
- Offer Letter, dated July 18, 2018 by and between the Company and Anthony G. Quinn (Filed With SEC on July 23, 2018)
- Offer Letter, dated June 20, 2017, issued by the Registrant to Dr. James Wooldridge (Filed With SEC on March 13, 2018)
- Offer Letter, dated August 31, 2017, issued by the Registrant to Dr. Anthony Quinn (Filed With SEC on November 7, 2017)
- Terms of Resignation between the Registrant and Dr. David G. Lowe (Filed With SEC on August 9, 2017)
- Offer Letter, dated April 21, 2017, issued by the Registrant to Dr. Anthony Quinn (Filed With SEC on May 9, 2017)
- Exhibit a (Filed With SEC on March 23, 2017)
- SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on November 9, 2016)
- SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on March 14, 2016)
